Current research developments of patient-derived tumour xenograft models (Review)

xlomafota13 shared this article with you from Inoreader Current research developments of patient-derived tumour xenograft models (Review) Via Experimental and therapeutic medicine Exp Ther Med. 2021 Nov;22(5):1206. doi: 10.3892/etm.2021.10640. Epub 2021 Aug 24. ABSTRACT Patient-derived tumor xenograft (PDTX) models are established by transferring patient tumors into immunodeficient mice. In these murine models, the characteristics of the primary tumor are retained, including the microenvironment of tumor cell growth and histopathology. Due to this, it has become the most reliable in vivo human cancer model. However, the success rates differ by type of tumor, site of transplantation and tumor aggressiveness. Subcutaneous transplantation is a standard method for PDTX, and subrenal capsule transplantation improves the engraftment rate. Recently, PDTX models are frequently used in the fields of precision medicine, predictive biomarkers, evaluation of drug efficacy and preclinical research on tumor immunotherapeutic drugs. The aim of the present article was to review the establishment, clinical applications an d limitations of the PDTX model in tumor research. PMID:34584551 | PMC:PMC8422395 | DOI:10.3892/etm.2021.10640 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.